172 related articles for article (PubMed ID: 27049891)
1. Psychometric testing of the Norwegian version of the Expanded Prostate Cancer Index Composite 26-item version (EPIC-26).
Fosså SD; Storås AH; Steinsvik EA; Myklebust TA; Eri LM; Loge JH; Dahl AA
Scand J Urol; 2016 Aug; 50(4):280-5. PubMed ID: 27049891
[TBL] [Abstract][Full Text] [Related]
2. Cross-cultural adaptation and validation of the French version of the Expanded Prostate cancer Index Composite questionnaire for health-related quality of life in prostate cancer patients.
Anota A; Mariet AS; Maingon P; Joly F; Bosset JF; Guizard AV; Bittard H; Velten M; Mercier M
Health Qual Life Outcomes; 2016 Dec; 14(1):168. PubMed ID: 27923377
[TBL] [Abstract][Full Text] [Related]
3. Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer.
Sibert NT; Dieng S; Oesterle A; Feick G; Carl G; Steiner T; Minner J; Roghmann F; Kaftan B; Zengerling F; Hinkel A; Beyer B; Heidenreich A; Harke N; Brehmer B; Pfitzenmaier J; Fichtner J; Neisius A; Hammerer P; Wesselmann S; Kowalski C
World J Urol; 2021 Jan; 39(1):11-25. PubMed ID: 31552467
[TBL] [Abstract][Full Text] [Related]
4. Psychometric Assessment of the Chinese Version of the Abbreviated Expanded Prostate Cancer Index Composite (EPIC-26) and the Clinical Practice Version (EPIC-CP) in Chinese Men With Prostate Cancer.
Lam WWT; Tse MA; Ng CNL; Chung EKM; Fielding R
J Pain Symptom Manage; 2017 Jun; 53(6):1085-1090. PubMed ID: 28438583
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
Wei JT; Dunn RL; Litwin MS; Sandler HM; Sanda MG
Urology; 2000 Dec; 56(6):899-905. PubMed ID: 11113727
[TBL] [Abstract][Full Text] [Related]
6. Portuguese version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): psychometric validation and prospective application for early functional outcomes at a single institution.
Lourenço DB; Amaral BS; Alfer-Junior W; Vasconcellos A; Russo F; Sanchez-Salas R; Bianco B; Wagner AA; Chang P; Moschovas MC; Lemos GC; Carneiro A
BMC Urol; 2020 Oct; 20(1):163. PubMed ID: 33081748
[TBL] [Abstract][Full Text] [Related]
7. Psychometric properties of the expanded prostate cancer index composite - 26 instrument in a cohort of radical prostatectomy patients: theoretical and practical examinations.
Axcrona K; Nilsson R; Brennhovd B; Sørebø Ø; Fosså SD; Dahl AA
BMC Urol; 2017 Dec; 17(1):111. PubMed ID: 29197360
[TBL] [Abstract][Full Text] [Related]
8. Psychometric validation of the Spanish version of the Expanded Prostate Cancer Index Composite-26.
Zamora V; Garin O; Suárez JF; Jové J; Castells M; Ferrer F; Gutiérrez C; Guedea F; Boladeras A; Fumadó L; Roselló A; Pastor J; Samper P; Pont À; Ferrer M
World J Urol; 2023 Dec; 41(12):3511-3518. PubMed ID: 37947846
[TBL] [Abstract][Full Text] [Related]
9. Validation of the Italian version of the abbreviated expanded prostate Cancer index composite (EPIC-26) in men with prostate Cancer.
Marzorati C; Monzani D; Mazzocco K; Masiero M; Pavan F; Monturano M; Pravettoni G
Health Qual Life Outcomes; 2019 Aug; 17(1):147. PubMed ID: 31464649
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain.
Zapatero A; Maldonado Pijoan X; Gómez-Caamaño A; Pardo Masferrer J; Macías Hernández V; Hervás Morón A; Muñoz García JL; Palacios Eito A; Anguita-Alonso P; González-Junco C; López Torrecilla J
Health Qual Life Outcomes; 2021 Sep; 19(1):223. PubMed ID: 34563208
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors.
Szymanski KM; Wei JT; Dunn RL; Sanda MG
Urology; 2010 Nov; 76(5):1245-50. PubMed ID: 20350762
[TBL] [Abstract][Full Text] [Related]
12. The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation.
Umbehr MH; Bachmann LM; Poyet C; Hammerer P; Steurer J; Puhan MA; Frei A
Health Qual Life Outcomes; 2018 Feb; 16(1):36. PubMed ID: 29458434
[TBL] [Abstract][Full Text] [Related]
13. [Quality of life in patients with prostate cancer: validation of an instrument for clinical practice].
Balbontín F; Marchetti P; Moreno S; Cabello JM; Urzúa C; Silva A; Avilés J; Badínez L; García J; Salgado A; Vinez E; Alliende I; Canals A; Velasco A
Arch Esp Urol; 2015 Jun; 68(5):466-73. PubMed ID: 26102050
[TBL] [Abstract][Full Text] [Related]
14. Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population.
Vigneault É; Savard J; Savard MH; Ivers H; Després P; Foster W; Martin AG; Fradet V
Can Urol Assoc J; 2017 Dec; 11(12):404-410. PubMed ID: 29106365
[TBL] [Abstract][Full Text] [Related]
15. Cultural adaptation and validation of the Chinese version of the expanded prostate cancer index composite.
Lee TK; Poon DMC; Ng ACF; Ho T; Singh-Carlson S; Joffres M; Oshan G; Kohli J; Kwan W
Asia Pac J Clin Oncol; 2018 Mar; 14 Suppl 1():10-15. PubMed ID: 29508938
[TBL] [Abstract][Full Text] [Related]
16. Validation of the Brazilian version of the Expanded Prostate Cancer Index Composite (EPIC) for patients submitted to radical prostatectomy.
Alves E; Medina R; Andreoni C
Int Braz J Urol; 2013; 39(3):344-52. PubMed ID: 23849583
[TBL] [Abstract][Full Text] [Related]
17. Cross validation of the prostate cancer radiotherapy late toxicity (PCRT) questionnaire with the expanded prostate cancer index composite (EPIC) instrument.
Rodrigues G; Bauman G; Venkatesan V; Ahmad B; Lock M; Sexton T; D'Souza D; Stitt L; Eid S
Can J Urol; 2011 Aug; 18(4):5802-10. PubMed ID: 21854712
[TBL] [Abstract][Full Text] [Related]
18. Creation and Psychometric Validation of the Sexual Minorities and Prostate Cancer Scale (SMACS) in Sexual Minority Patients-The Restore-2 Study.
Polter EJ; Kohli N; Rosser BRS; Talley KMC; Wheldon CW; Hoefer CJ; Wright M; Haggart R; Mitteldorf D; Kilian G; Konety BR; Ross MW; West W
J Sex Med; 2022 Mar; 19(3):529-540. PubMed ID: 35131199
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the quality of life of patients with localizad prostate cancer: validation of the Spanish version of the EPIC].
Ferrer M; Garin O; Pera J; Prats JM; Mendivil J; Alonso J; De Paula B; Herruzo I; Hervas A; Macias V; Mariño A; Ortiz MJ; Pastor S; Ponce De León J; Sancho G;
Med Clin (Barc); 2009 Feb; 132(4):128-35. PubMed ID: 19211071
[TBL] [Abstract][Full Text] [Related]
20. Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer.
Einstein DJ; Patil D; Chipman J; Regan MM; Davis K; Crociani CM; Wagner AA; Sanda MG; Chang P
Urology; 2019 May; 127():53-60. PubMed ID: 30790648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
